Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Artemis first-line carboplatin + paclitaxel + lenvatinib + pembrolizumab for advanced or recurrent thymic carcinoma
jRCT2031230114Suspended
- Sponsor
- Merck & Co.
- Start
- Oct 2023
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of carboplatin, paclitaxel, pembrolizumab and lenvatinib in thymic carcinoma (TC), sponsored by Merck & Co. Primary endpoint: Objective response rate. Started Oct 2023; status: suspended.
02
Drugs
03
Conditions
thymic carcinoma (TC)
Beyond the preview
Go deeper on jRCT2031230114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230114.